Haemonetics HAE has been benefiting from business growth within Plasma, Hospital and Hemostasis Management. New launches are also aiding growth. The stock carries a Zacks Rank #1 (Strong Buy).
Good day, and thank you for standing by. Welcome to the Q4 2024 Haemonetics Corporation Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' ...
AlphaQuest LLC boosted its position in shares of Haemonetics Co. (NYSE:HAE – Free Report) by 36,520.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results